Radiotherapy and radiation oncology play a key role in the clinical management of patients
suffering from oncological diseases. In clinical routine, anatomic imaging such as contrast …

The introduction of novel therapeutic agents for advanced prostate cancer has led to a wide
range of treatment options for patients with metastatic castration-resistant prostate cancer …

Importance The presence of pelvic nodal metastases at radical prostatectomy is associated
with biochemical recurrence after prostatectomy. Objective To assess the accuracy of …

Background Previously, results from the TheraP trial showed that treatment with lutetium-177
[177 Lu] Lu-PSMA-617 improved frequency of prostate-specific antigen (PSA) response rate …

Background In VISION, the prostate-specific membrane antigen (PSMA)-targeted
radioligand therapy lutetium-177 [177 Lu] Lu-PSMA-617 (vipivotide tetraxetan) improved …

Summary Background Actinium-225 (225 Ac) prostate-specific membrane antigen (PSMA)
radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate …

Summary Background [177 Lu] Lu-PSMA-617 (177 Lu-PSMA-617) prolongs radiographic
progression-free survival and overall survival in patients with metastatic castration-resistant …

PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer,
making it an excellent target for imaging and treating patients with prostate cancer. Several …

Rationale Prolonged in vivo evaluation of PSMA tracers could improve tumor imaging and
patient selection for 177 Lu-PSMA-617 and 177 Lu-PSMA-I&T. In this study, we present the …

Purpose Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) is a novel
treatment for castration-resistant prostate cancer (mCRPC). While the majority of patients …